The secret to winning cannabis M&A is infrastructure, not scale

Matthew Myro Rothman (Courtesy photo)

(This is a contributed guest column. To be considered as an MJBizDaily guest columnist, please submit your request here.)

After a quiet period, cannabis M&A activity is back. Following President Donald Trump’s December executive order directing cannabis rescheduling, marijuana multistate operators are acquiring distressed assets and expanding footprints across mature markets. Consolidation is framed as a sign of renewed confidence.

On paper, the logic is easy to understand: more stores, more states, more delivery infrastructure. But scale doesn’t fix what’s broken in cannabis retail.

Many of the assets changing hands weren’t underperforming because they lacked brand recognition or reach. They were struggling because the economics no longer worked.

High customer acquisition costs, relentless discounting, thinning margins and inconsistent customer retention have become structural issues — not cyclical ones.

Rebranding a distressed store doesn’t change that math.

The risk in today’s consolidation wave isn’t that operators are moving too fast. It’s that they’re applying the same retail playbook to a market that increasingly behaves less like discretionary retail and more like necessary health care.

Why consolidation doesn’t guarantee growth for cannabis operators

In traditional retail, scale can unlock efficiencies: purchasing power, logistics optimization, marketing leverage.

Cannabis has chased that model for years despite the constraints federal prohibition creates for siloed state markets.

The problem is that cannabis demand, particularly on the medical side, doesn’t behave like footwear, electronics or food delivery.

Patients are not always shoppers hunting for the best promotion. They’re seeking consistency, trust, clinical validation, improved outcomes and continuity of care.

Discount-driven acquisition strategies may spike short-term traffic, but they rarely produce durable customer relationships.

In a compressed pricing environment, that approach becomes self-defeating. Consolidation without a responsive demand engine risks creating larger versions of struggling businesses.

More storefronts don’t matter if customer lifetime value continues to erode. More delivery routes don’t help if each order costs more to acquire than it returns in margin.

What’s the new model for cannabis retail?

Many operators already sense this shift, even if they haven’t named it yet.

Cannabis retail is moving toward a health care-adjacent model, whether the industry fully embraces that reality or not.

The slow and steady move towards classifying cannabis as a medicine is just one proof point.

Another is the quiet expansion of health-benefit reimbursement models that allow registered medical cannabis patients to recoup costs through employer-sponsored or insurer-backed programs, fundamentally changing how and why patients engage.

Health care markets prioritize patient pipelines over foot traffic. They value retention over one-time conversion. They invest in systems that reduce friction and normalize access rather than relying on promotions to stimulate demand.

Most importantly, they build infrastructure that supports repeat engagement without escalating marketing spend.

When operators evaluate acquisitions purely on store count, square footage or historical delivery volume, they risk missing the long view: How does this asset draw consumers and maintain loyalty without racing to the bottom on price?

What should cannabis operators evaluate before the next acquisition?

As consolidation continues, operators and investors would benefit from framing their due diligence process around a few practical questions:

• How does this asset acquire customers without relying on discounts or constant promotions?
• What percentage of revenue comes from repeat customers versus one-time buyers?
• How resilient is demand if advertising channels tighten or promotional activity is reduced?
• Does the operation support medical patients in a way that encourages long-term engagement, not transactional visits?

These questions matter more than ever in mature markets where growth is no longer driven by novelty or rapid license expansion.

Healthcare-style infrastructure, not branding, is the competitive edge in cannabis

The next phase of cannabis growth won’t be won by the loudest brands or the largest footprints. It will be shaped by operators equipped with systems that change how customers enter the market — and stay there.

That means shifting focus from marketing tactics to infrastructure: tools and processes that support compliance, patient trust, reimbursement pathways for registered patients and consistent engagement. These systems stabilize and improve margins.

Retail tactics still matter, but they’re no longer sufficient. Operators must begin building for a healthcare-adjacent model, not a retail-only one.

Consolidation can be a powerful strategy to break stagnation. But it isn’t a strategy by itself.

Without a fundamental shift in how demand is created and sustained, today’s acquisition wave risks scaling the same failure-prone modes that created distress in the first place.

Operators who recognize this now — and invest in health-oriented infrastructure that supports consistent, recurring patient engagement — will be better positioned to build businesses that endure beyond the next market cycle.

Gennaro Luce is the CEO of CannaLnx by EM2P2, the first HIPAA-compliant digital platform that connects patients, doctors and dispensaries with insurers. Matthew Myro Rothman is the company’s Chief Science Officer.